Skip to main content
. 2014 Nov 18;14:294. doi: 10.1186/s12870-014-0294-3

Table 1.

Inhibition (%) of protease activity by actively and non-actively transcribed cystatins during nodule life-span

Cystatin Cathepsin L-like activity Cathepsin B-like activity
(% inhibition) (% inhibition)
4 weeks 8 weeks 14 weeks p ≤ 0.05 4 weeks 8 weeks 14 weeks p ≤ 0.05
Positive control (E64) 50.3 ± 1.1 26.4 ± 5.0 31.9 ± 4.5 *ac 37.2 ± 2.3 NI NI *ac
OCI (1 μM) 47.4 ± 1.3 28.2 ± 2.3 22.7 ± 7.3 *ac 44.9 ± 3.8 NI NI *ac
Actively transcribed
Glyma05g28250 36.1 ± 0.5 31.5 ± 0.9 30.6 ± 0.4 ns 32.8 ± 1.4 32.8 ± 1.4 NI *bc
Glyma13g04250 26.4 ± 0.9 NI 29.7 ± 1.8 *ab 27.6 ± 2.3 27.6 ± 2.3 24.9 ± 3.2 *ab
Glyma13g27980 33.2 ± 2.3 NI NI *ac 42.0 ± 0.2 42.0 ± 0.2 NI *ac
Glyma14g04250 NI NI 21.9 ± 1.6 *bc NI NI NI ns
Glyma15g36180 49.9 ± 5.3 28.4 ± 3.1 NI *abc 48.7 ± 4.5 48.7 ± 4.5 NI *ac
Glyma20g08800 NI NI NI ns NI NI 32.5 ± 3.2 *ab
Non-actively transcribed
Glyma04g10360 38.6 ± 2.9 32.0 ± 3.9 39.0 ± 3.5 ns 35.3 ± 5.5 30.9 ± 5.5 28.6 ± 5.8 ns
Glyma07g39590 47.5 ± 3.2 39.1 ± 9.5 51.3 ± 5.1 *b 42.3 ± 5.3 26.9 ± 8.7 34.0 ± 2.9 *a
Glyma08g11210 43.6 ± 3.8 28.2 ± 1.8 33.5 ± 4.3 *abc 42.1 ± 4.4 NI NI *ac
Glyma14g04260 58.9 ± 1.1 37.8 ± 4.9 36.2 ± 3.3 *ac 46.4 ± 1.8 NI NI *ac
(1st domain)
Glyma14g04260 36.6 ± 4.9 NI NI *ac 39.8 ± 5.6 NI NI *ac
(2nd domain)
Glyma14g04291 42.1 ± 3.3 NI NI *ac 30.9 ± 5.6 NI NI *ac
(1st domain)
Glyma14g04291 40.8 ± 8.3 NI NI *ac 28.6 ± 8.4 NI NI *ac
(2nd domain)
Glama18g12240 54.0 ± 2.6 43.1 ± 1.9 51.5 ± 3.7 *a 36.6 ± 5.8 28.3 ± 3.9 22.4 ± 7.4 *c

*a (4 weeks – 8 weeks); *b (8 weeks – 14 weeks); *c (4 weeks −14 weeks); NI represents inhibition ≥20%; *significant at p ≤0.05. Blank values for Cathepsin L-like activity and Cathepsin B-like activity was 0.5 ± 0.7 FU/sec and 0.0 ± 0.3 FU/sec, respectively. The negative control values for Cathepsin L-like activity and Cathepsin B-like activity was 42.5 ± 1.6 FU/sec and 28.2 ± 0.8 FU/sec, respectively.